The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | — | 20.1x | Near average | |
Growth | 48 | — | 5.6% | Near average | |
Quality | 12 | -79.2% | 7.6% | Below average | |
Safety | 29 | 0.4x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Acrivon Therapeutics, Inc. Common Stock is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Acrivon Therapeutics, Inc. Common Stock shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ACRV stock shows stability in the average price target at $21.83, representing a very significant gap compared to the current price ($1.75), reflecting excessive optimism from the analysts following the stock despite their small number. Price targets have not seen any changes over the past 30 days, with a notable Dispersion between the upper limit of $30 and the lower limit of $17, indicating uncertainty regarding the timeline for value realization.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.